ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Jounce Therapeutics Receives FDA Clearance of Investigational NDA for Anti-CCR8 Antibody
June 17, 2021Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the U.S. FDA's clearance of its Investigational New Drug (IND) application for JTX-1811 ... -
Gilead Sciences Signs Agreement with Jounce Therapeutics
September 03, 2020Gilead Sciences Inc. has signed an agreement with Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program. -
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program
September 02, 2020Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop JTX-1811.
Pharma Sources Insight January 2025
